Yahoo! Finance: Biotechnology Industry News: Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

TypePad Has the Tools Looking for a premiere blogging service? Start your blog today on TypePad. From our sponsors

Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation Nov 2nd 2013, 13:01 [Business Wire] - Gilead Sciences, Inc. today announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue sofosbuvir plus ribavirin for both the prevention and treatment of recurrent chronic hepatitis C virus infection among patients who undergo liver transplantation.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions